Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03845270

Recruitment Status : Recruiting

First Posted : February 19, 2019

Last Update Posted : September 2, 2019

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Intergroupe Francophone de Cancerologie Thoracique

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	December 2020
Estimated Study Completion Date :	March 2022

To Top